Saracatinib Gives Brand-New Life To An Old Topic- Defacto Standardized

Samples were normalized to human ��-actin as an endogenous reference. Significantly more human IL-6 mRNA levels were detected in organ metastases, when compared with the primary tumor (p http://www.selleckchem.com/products/cx-5461.html highly expressed. Metastasis of breast cancer to brain is generally a late feature of metastatic disease [23], which may explain why we did not detect micrometastases in the brain using immunohistochemistry. To address whether breast cancer metastases formed in brain and whether NSCs migrated to these tumor cells, we used a sensitive molecular approach (PCR) to detect the presence of minimal numbers of tumors cells and NSCs. We used hemi-nested PCR to detect the v-myc gene present in NSCs and single-step PCR to detect luc gene present in tumor cells. PCR http://www.selleck.cn/products/AZD0530.html for luc gene revealed a positive band in primary tumors and metastases that were detectable by immunohistochemistry, and also in brain (Fig. 5E), which suggests that only few breast cancer cells had metastasized to the brain at the time when mice were euthanized. Tumor metastases to the brain might become detectable by immunohistochemistry at a later stage of disease. PCR to detect the v-myc gene, a marker for HB1.F3.CD NSCs, indicated http://www.selleckchem.com/products/forskolin.html the presence of NSCs in the primary tumor as well as in metastases, including the lymph nodes, lung, liver, femur, and brain (Fig. 5E). The band indicating the presence of v-myc in the brain was of low intensity, but, nevertheless, it indicated that NSCs can target breast cancer micrometastases in the brain. To confirm the specificity of the PCR, we used DNA isolated from brain of a nontumor-bearing mouse that had been injected intracranially with HB1.F3.CD NSCs as positive control, and as a negative control, we used DNA from the brain of a na?ve mouse. We detected an intense v-myc band in the positive control brain but not in the negative control (data not shown). Taken together, these data indicate that NSCs localize to hard-to-treat breast cancer metastases, including brain and bone, and therefore may be useful as drug delivery vehicles for treatment of advanced breast cancer. For therapeutic studies, NSCs were genetically modified to secrete rCE, which activates the prodrug CPT-11 to the active drug SN-38, to provide tumor-localized therapeutic drug delivery. Human HB1.F3.CD NSCs were transduced with replication-deficient adenovirus to express rCE (NSC.rCE), and expression of functionally active, secreted rCE was quantified by assessing the CE activity in conditioned medium.